Skip to main content
Erschienen in:

24.01.2022 | Nephrology - Original Paper

Hyperuricemia aggravates the progression of IgA nephropathy

verfasst von: Yin-Hong Geng, Zhe Zhang, Jun-Jun Zhang, Bo Huang, Zui-Shuang Guo, Xu-Tong Wang, Lin-Qi Zhang, Song-Xia Quan, Rui-Min Hu, Ya-Fei Liu

Erschienen in: International Urology and Nephrology | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

The relationship between hyperuricemia and IgA nephropathy (IgAN) was evaluated systematically in this research.

Methods

The Preferred Reporting Items for Systematic Review and Meta-analysis statement was employed to design and report the study.

Results

Twenty-five studies were included in this meta-analysis with a total of 6048 IgAN patients. The clinical indicators indicated that blood urea nitrogen (BUN) (p < 0.00001, mean difference (MD) = 2.60, 95% confidence interval (CI) 1.74–3.46), serum creatinine (Scr) (p < 0.00001, MD = 44.56, 95% CI 31.15–57.98), diastolic blood pressure(DBP) (p < 0.00001, MD = 3.86, 95% CI 2.84–4.88), systolic blood pressure(SBP) (p < 0.00001, MD = 6.71, 95% CI 4.70–8.71), and 24-h urine protein(24 h TP) (p < 0.00001, MD = 0.76, 95% CI 0.58–0.94) were significantly increased in IgAN with hyperuricemia group than that in normouricemic IgAN group. The pathological analysis indicated that mesangial proliferation (p < 0.00001, MD = 0.12, 95% CI 0.07–0.17), vascular lesion (p < 0.00001, MD = 0.17, 95% CI 0.13–0.20), segmental lesion (p < 0.00001, MD = 0.15, 95% CI 0.03–0.26), tubulointerstitial damage (p < 0.00001, MD = 1.27, 95% CI 1.06–1.48), and glomerulosclerosis (p < 0.00001, MD = 0.56, 95% CI 0.40–0.72) were considerably climbed in IgAN patients with hyperuricemia compared without hyperuricemia group. Additionally, the estimated glomerular filtration rate (p < 0.00001, MD = − 29.03, 95% CI − 36.83 to − 21.23) was decreased in IgAN patients with hyperuricemia compared with normouricemic group.

Conclusion

Hyperuricemia exacerbates IgAN prognosis through aggravating the clinical outcomes and pathological results of IgAN.
Literatur
3.
Zurück zum Zitat Liang MJ, Ou M, Chen XM, Zhang W, Chen W, Yang QQ et al (2013) Prevalence rate of hyperuricemia and its related risk factors in patients with IgA nephropathy. Chinese Journal of Nephrology 05:326–332 Liang MJ, Ou M, Chen XM, Zhang W, Chen W, Yang QQ et al (2013) Prevalence rate of hyperuricemia and its related risk factors in patients with IgA nephropathy. Chinese Journal of Nephrology 05:326–332
6.
Zurück zum Zitat Iseki K, Ikemiya Y et al (2004) Significance of hyperuricemia as a risk factor for developing ESRD in a Screened cohort. Am J Kidney Dis 44(4):642–650CrossRef Iseki K, Ikemiya Y et al (2004) Significance of hyperuricemia as a risk factor for developing ESRD in a Screened cohort. Am J Kidney Dis 44(4):642–650CrossRef
11.
Zurück zum Zitat Ancharaz preeatum (2016) The role of serum uric acid in the progression of IgA nephropathy: a systematic review and meta-analysis. Dalian Medical University, MA thesis. Ancharaz preeatum (2016) The role of serum uric acid in the progression of IgA nephropathy: a systematic review and meta-analysis. Dalian Medical University, MA thesis.
13.
Zurück zum Zitat Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C et al (2012) Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transpl 27(4):1479–1485. https://doi.org/10.1093/ndt/gfr527CrossRef Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C et al (2012) Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transpl 27(4):1479–1485. https://​doi.​org/​10.​1093/​ndt/​gfr527CrossRef
16.
Zurück zum Zitat Cui MJ, Zhang BH, Xiao QF, Zhu FL, Wang HY (2011) The relationship between hyperuricaemia and clinic pathology of IgA nephropathy. Zhonghua Nei Ke Za Zhi 50(8):659–663PubMed Cui MJ, Zhang BH, Xiao QF, Zhu FL, Wang HY (2011) The relationship between hyperuricaemia and clinic pathology of IgA nephropathy. Zhonghua Nei Ke Za Zhi 50(8):659–663PubMed
20.
Zurück zum Zitat Cai L, Bai Y (2014) study on hyperuricemia and its risk factors in patients with IgA nephropathy. Chin Commun Physician 30(06):118–119 Cai L, Bai Y (2014) study on hyperuricemia and its risk factors in patients with IgA nephropathy. Chin Commun Physician 30(06):118–119
21.
Zurück zum Zitat Cai WC, Han SL, Guo XD, Ling YS, Liu JL, Guan TJ (2016) Clinicopathological analysis of et al. IgA nephropathy complicated with hyperuricemia. J Clin Nephrol 16(03):152–156 Cai WC, Han SL, Guo XD, Ling YS, Liu JL, Guan TJ (2016) Clinicopathological analysis of et al. IgA nephropathy complicated with hyperuricemia. J Clin Nephrol 16(03):152–156
22.
Zurück zum Zitat Cai Y, Ni M, Liao HF, Yang C, Li YJ, Li WB (2019) Clinicopathological study of et al. IgA nephropathy complicated with hyperuricemia. China Pract Med 14(12):44–46 Cai Y, Ni M, Liao HF, Yang C, Li YJ, Li WB (2019) Clinicopathological study of et al. IgA nephropathy complicated with hyperuricemia. China Pract Med 14(12):44–46
23.
Zurück zum Zitat Chen YP, Liang YF (2017) Study on the relationship between hyperuricemia and prognosis of patients with IgA nephropathy. Prim Med Forum 21(01):63–65 Chen YP, Liang YF (2017) Study on the relationship between hyperuricemia and prognosis of patients with IgA nephropathy. Prim Med Forum 21(01):63–65
24.
Zurück zum Zitat Fan H, Liu F, Kong RZ, Yu J, Liu YY (2017) Analysis of clinical and pathological correlation between serum uric acid of IgA nephropathy. China Expe Diagn 21(09):1563–1565 Fan H, Liu F, Kong RZ, Yu J, Liu YY (2017) Analysis of clinical and pathological correlation between serum uric acid of IgA nephropathy. China Expe Diagn 21(09):1563–1565
25.
Zurück zum Zitat Gao XY (2013) Analysis of clinicopathological factors of hyperuricemia in IgA nephropathy. Jiangsu Med J 39(23):2907–2908 Gao XY (2013) Analysis of clinicopathological factors of hyperuricemia in IgA nephropathy. Jiangsu Med J 39(23):2907–2908
26.
Zurück zum Zitat Lian XY, Huang SH, Zhao JT, Yang M (2010) Clinicopathological analysis of patients with IgA nephropathy complicated with hyperuricemia. J Pract Med 26(14):2667–2668 Lian XY, Huang SH, Zhao JT, Yang M (2010) Clinicopathological analysis of patients with IgA nephropathy complicated with hyperuricemia. J Pract Med 26(14):2667–2668
27.
Zurück zum Zitat Liu CY, Zhou XL, Chen MH (2011) Relationship between hyperuricemia and clinicopathology of IgA nephropathy and its influencing factors. Ningxia Med J 33(08):701–703 Liu CY, Zhou XL, Chen MH (2011) Relationship between hyperuricemia and clinicopathology of IgA nephropathy and its influencing factors. Ningxia Med J 33(08):701–703
28.
Zurück zum Zitat Liu HF, Wang XH, Lu J, Cai CT, Xu XL (2020) Hyperuricemia on clinical and pathological features of IgA nephropathy. CJITWN 21(01):47–49 Liu HF, Wang XH, Lu J, Cai CT, Xu XL (2020) Hyperuricemia on clinical and pathological features of IgA nephropathy. CJITWN 21(01):47–49
29.
Zurück zum Zitat Liu XD (2012) Analysis of the effect of serum uric acid on clinicopathology and prognosis of IgA nephropathy. Guide China Med 10(21):557–558 Liu XD (2012) Analysis of the effect of serum uric acid on clinicopathology and prognosis of IgA nephropathy. Guide China Med 10(21):557–558
30.
Zurück zum Zitat Lou Y, Gao D, Wei YL, Liu SJ, Tian XH (2018) IgA nephropathy complicated with hyperuricemia: clinical and pathological features. China Exp Diagn 22(04):661–663 Lou Y, Gao D, Wei YL, Liu SJ, Tian XH (2018) IgA nephropathy complicated with hyperuricemia: clinical and pathological features. China Exp Diagn 22(04):661–663
31.
Zurück zum Zitat Ni L (2018) Study on the effect of hyperuricemia on IgA nephropathy. Chin Contemp Med 25(16):72–74 Ni L (2018) Study on the effect of hyperuricemia on IgA nephropathy. Chin Contemp Med 25(16):72–74
32.
Zurück zum Zitat Nie P, Dong CQ, Guan Y, Luo P (2016) With hyperuricemia IgA nephropathy clinical and pathological analysis. J Changchun Univ Tradit Chin Med 32(03):614–615 Nie P, Dong CQ, Guan Y, Luo P (2016) With hyperuricemia IgA nephropathy clinical and pathological analysis. J Changchun Univ Tradit Chin Med 32(03):614–615
33.
Zurück zum Zitat Shen SZ, Wu JP, Yang ZM, Cai JY, Hu YY, Kong LY et al (2013) Clinical and pathological analysis of IgA nephropathy with hyperuricemia. J Clin Nephrol 13(4):174–175 Shen SZ, Wu JP, Yang ZM, Cai JY, Hu YY, Kong LY et al (2013) Clinical and pathological analysis of IgA nephropathy with hyperuricemia. J Clin Nephrol 13(4):174–175
34.
Zurück zum Zitat Tian Y, Zhuo L, Li WG, Zhou GM, Lu JH (2012) Clinical and pathological features of IgA nephropathy complicated with hyperuricemia. Beijing Med 34(04):257–259 Tian Y, Zhuo L, Li WG, Zhou GM, Lu JH (2012) Clinical and pathological features of IgA nephropathy complicated with hyperuricemia. Beijing Med 34(04):257–259
35.
Zurück zum Zitat Wang X, Chen Y (2017) Analysis of clinical and pathological features of primary IgA nephropathy with hyperuricemia. Mil Med J Southeast China 19(06):600–603 Wang X, Chen Y (2017) Analysis of clinical and pathological features of primary IgA nephropathy with hyperuricemia. Mil Med J Southeast China 19(06):600–603
36.
Zurück zum Zitat Yang RQ, Huang SS, Lai H, Zhang J, Li QY, Zeng JM et al (2018) Clinical and pathological analysis of et al. IgA nephropathy complicated with hyperuricemia. Heilongjiang Med 42(04):295–298 Yang RQ, Huang SS, Lai H, Zhang J, Li QY, Zeng JM et al (2018) Clinical and pathological analysis of et al. IgA nephropathy complicated with hyperuricemia. Heilongjiang Med 42(04):295–298
37.
Zurück zum Zitat Zhang YZ, Liu DJ (2018) Analysis of clinical and pathological features of patients with IgA nephropathy complicated with hyperuricemia. CJITWN 19(10):911–913 Zhang YZ, Liu DJ (2018) Analysis of clinical and pathological features of patients with IgA nephropathy complicated with hyperuricemia. CJITWN 19(10):911–913
38.
Zurück zum Zitat Zhao MJ, Jn JF, Zhang XY, Shen ZY, Zhang H, Yu JY et al (2016) Clinical and pathological analysis of et al. IgA nephropathy complicated with hyperuricemia. Shanghai Med 39(05):265–271 Zhao MJ, Jn JF, Zhang XY, Shen ZY, Zhang H, Yu JY et al (2016) Clinical and pathological analysis of et al. IgA nephropathy complicated with hyperuricemia. Shanghai Med 39(05):265–271
43.
Zurück zum Zitat Zhu WL (2010) Interpretation of expert consensus on diagnosis and treatment of hyperuricemia combined with cardiovascular disease. Chin J Cardiol 15(06):412–414 Zhu WL (2010) Interpretation of expert consensus on diagnosis and treatment of hyperuricemia combined with cardiovascular disease. Chin J Cardiol 15(06):412–414
45.
Zurück zum Zitat Liao Y, Xu RC, Hu HF, Song HY, Wan QJ (2019) Relationship between serum uric acid level and Clinicopathology in IgA nephropathy with massive proteinuria [J]. Chin J Physicians 21(12):1863–1865 Liao Y, Xu RC, Hu HF, Song HY, Wan QJ (2019) Relationship between serum uric acid level and Clinicopathology in IgA nephropathy with massive proteinuria [J]. Chin J Physicians 21(12):1863–1865
50.
Zurück zum Zitat Lv DY, Shao XF, Li YQ, Zou HQ (2019) Correlation between mild hyperuricemia and glomerular filtration rate and urinary albumin creatinine ratio [J]. J Bengbu Med Coll 44(07):890–896 Lv DY, Shao XF, Li YQ, Zou HQ (2019) Correlation between mild hyperuricemia and glomerular filtration rate and urinary albumin creatinine ratio [J]. J Bengbu Med Coll 44(07):890–896
Metadaten
Titel
Hyperuricemia aggravates the progression of IgA nephropathy
verfasst von
Yin-Hong Geng
Zhe Zhang
Jun-Jun Zhang
Bo Huang
Zui-Shuang Guo
Xu-Tong Wang
Lin-Qi Zhang
Song-Xia Quan
Rui-Min Hu
Ya-Fei Liu
Publikationsdatum
24.01.2022
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 9/2022
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-022-03125-4

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Vorhofflimmern: Antikoagulation vor Schlaganfall von Vorteil

Erleiden Menschen mit Vorhofflimmern einen ischämischen Schlaganfall, ist dieser weniger schwer, auch sind Infarktgröße und Blutungsrisiko geringer, wenn sie zuvor orale Antikoagulanzien erhalten haben. Die Art der Antikoagulation spielt dabei keine Rolle.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Mehr Cholesterin im Essen = höheres Herzinfarktrisiko

Je mehr Cholesterin man täglich über die Nahrung zu sich nimmt, desto höher ist offenbar das Herzinfarktrisiko – das legt eine Studie mit US-Veteranen zumindest für Männer nahe.

Antikoagulation bei Vorhofflimmern: Sind DOAK noch zu toppen?

Gegen Thromboembolien so wirksam wie ein DOAK, bei zugleich geringerem Blutungsrisiko – werden Faktor-XI-Hemmer als neue Antikoagulanzien dieser Erwartung gerecht? Eine aktuell publizierte Vergleichsstudie gibt darüber Aufschluss.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.